Company intelligence / Profile preview

MiGenTra

Ownership: Private
Development stage: Other

Overview

MiGenTra develops and manufactures affordable biologics—including biosimilars—and cell/gene therapies for the Middle East and Africa. The company leverages advanced manufacturing from ProBioGen and regional market access via Minapharm. It has commercialized products in recombinant proteins with ongoing expansion into new modalities such as vaccines and gene/cell therapies. Detailed clinical results are not publicly disclosed.

Therapeutic areas: HematologyGastroenterologyOncologyImmunologyWomen's Health
Modalities: BiologicBiosimilarCell therapyGene therapyVaccine
Industry: Biotech

Drug pipeline

6 assets

Zevaria

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

ProBioGen AGMinapharm Pharmaceuticals SEcollaborates with biopharma partners for commercialization in MEA region

Beyond the preview

Go deeper on MiGenTra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MiGenTra.

Explore the full profile